A Defense of the Private Sector
Nathan Risinger
|
Posted 01.08.2013
|
World
Pfizer Inc.'s decision to shelve a novel insulin inhaler and take a $2.8 billion pretax hit on the product -- one of the drug industry's costliest fai...